S&P Futures
4,038.25 +5.75 (+0.14%) Dow Futures
33,818.00 +33.00 (+0.10%) Nasdaq Futures
11,969.25 +1.25 (+0.01%) Russell 2000 Futures
1,897.40 +3.90 (+0.21%) Crude Oil
77.20 -0.70 (-0.90%) Gold
1,927.70 -11.50 (-0.59%)
WisdomTree U.S. SmallCap Price (^WTSEI)
| Previous Close | 585.89 |
| Open | 0.00 |
| Volume |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Avg. Volume | N/A |
- PR Newswire
FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress. NRx Pharmaceuticals had submitted this last EUA application using data from a post-hoc subgroup analysis.
- PR Newswire
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting a virtual update to the company's business via webcast at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond. This presentation provides an update for the Company's lead therapeutic product, NRX-101, targeting Bipolar D
- PR Newswire
Class Action Suit Against NRx Pharmaceuticals Dismissed
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned "Dal Bosco v. NRx Pharmaceuticals, Inc. et al." filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers. The dismissal was made without prejudice.
